晚期卵巢癌耐药相关基因单核苷酸多态性与化疗反应的相关性
Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.
作者信息
Obata Hiroaki, Yahata Tetsuro, Quan Jinhua, Sekine Masayuki, Tanaka Kenichi
机构信息
Division of Molecular Genetics, Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan.
出版信息
Anticancer Res. 2006 May-Jun;26(3B):2227-32.
BACKGROUND
Single nucleotide polymorphisms (SNPs) may show clinicopathological importance as prognostic markers. This study examined the association of SNPs and the expression of drug resistance-associated markers with response to chemotherapy in advanced ovarian cancer (stages III and IV) patients.
MATERIALS AND METHODS
SNPs were analyzed for MDR1, MRP1, MRP2 and LRP in 60 advanced ovarian cancer patients. The protein expression of each factor was analyzed by immunohistochemistry in all patients.
RESULTS
As a result of examining the relevance of SNP genotypes to the response to chemotherapy, a significant relevance (p=0.01) was observed regarding MRP1 exon-17 SNP (G2168A) involving amino acid substitution. No significant relationship was observed between protein expression and the response to chemotherapy or disease-free survival time.
CONCLUSION
Analysis of drug resistance gene polymorphism appears to be an indicator of the response to chemotherapy in advanced ovarian cancer.
背景
单核苷酸多态性（SNP）作为预后标志物可能具有临床病理重要性。本研究检测了晚期卵巢癌（III期和IV期）患者中SNP与耐药相关标志物的表达和化疗反应之间的关联。
材料与方法
对60例晚期卵巢癌患者的多药耐药基因1（MDR1）、多药耐药相关蛋白1（MRP1）、多药耐药相关蛋白2（MRP2）和肺耐药蛋白（LRP）进行SNP分析。对所有患者通过免疫组织化学分析各因子的蛋白表达。
结果
通过检测SNP基因型与化疗反应的相关性，发现涉及氨基酸替代的MRP1外显子17 SNP（G2168A）存在显著相关性（p = 0.01）。未观察到蛋白表达与化疗反应或无病生存时间之间存在显著关系。
结论
耐药基因多态性分析似乎是晚期卵巢癌化疗反应的一个指标。
Zotero 插件